Healthcare-associated pneumonia in adults: management principles to improve outcomes

被引:42
作者
Craven, DE
Palladino, R
McQuillen, DP
机构
[1] Lahey Clin Med Ctr, Dept Infect Dis, Burlington, MA 01805 USA
[2] Tufts Univ, Sch Med, Boston, MA 02118 USA
[3] Lahey Clin Med Ctr, Dept Pulm & Crit Care Med, Burlington, MA 01805 USA
关键词
D O I
10.1016/j.idc.2004.08.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Patients with healthcare-associated pneumonia include those with hospital-acquired pneumonia, those with ventilator-associated pneumonia, those who were hospitalized in an acute care hospital for at least 2 days within 90 days of the infection, and those who have resided in a nursing home or long-term care facility. Infection with multidrug-resistant (MDR) pathogens may result in a delay in initiating appropriate antibiotic therapy, which in turn may increase patient morbidity and mortality and hospital costs. This article primarily addresses principles of management to improve patient outcomes and reduce the emergence of MDR pathogens.
引用
收藏
页码:939 / +
页数:25
相关论文
共 80 条
  • [1] Tablan Ofelia C, 2004, MMWR Recomm Rep, V53, P1
  • [2] ACE inhibitors and symptomless dysphagia
    Arai, T
    Yasuda, Y
    Takaya, T
    Toshima, S
    Kashiki, Y
    Yoshimi, N
    Fujiwara, H
    [J]. LANCET, 1998, 352 (9122) : 115 - 116
  • [3] Angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, and pneumonia in elderly hypertensive patients with stroke
    Arai, T
    Yasuda, Y
    Takaya, T
    Toshima, S
    Kashiki, Y
    Yoshimi, N
    Fujiwara, H
    [J]. CHEST, 2001, 119 (02) : 660 - 661
  • [4] Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin:: A multicenter, randomized controlled trial
    Brun-Buisson, C
    Sollet, JP
    Schweich, H
    Brière, S
    Petit, C
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) : 346 - 354
  • [5] Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711
  • [6] NOSOCOMIAL PNEUMONIA - A MULTIVARIATE-ANALYSIS OF RISK AND PROGNOSIS
    CELIS, R
    TORRES, A
    GATELL, JM
    ALMELA, M
    RODRIGUEZROISIN, R
    AGUSTIVIDAL, A
    [J]. CHEST, 1988, 93 (02) : 318 - 324
  • [7] Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial
    Chastre, J
    Wolff, M
    Fagon, JY
    Chevret, S
    Thomas, F
    Wermert, D
    Clementi, E
    Gonzalez, J
    Jusserand, D
    Asfar, P
    Perrin, D
    Fieux, F
    Aubas, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (19): : 2588 - 2598
  • [8] Ventilator-associated pneumonia
    Chastre, J
    Fagon, JY
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (07) : 867 - 903
  • [9] ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY
    CHOW, JW
    FINE, MJ
    SHLAES, DM
    QUINN, JP
    HOOPER, DC
    JOHNSON, MP
    RAMPHAL, R
    WAGENER, MM
    MIYASHIRO, DK
    YU, VL
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) : 585 - 590
  • [10] PROSPECTIVE RANDOMIZED COMPARISON OF IMIPENEM MONOTHERAPY WITH IMIPENEM PLUS NETILMICIN FOR TREATMENT OF SEVERE INFECTIONS IN NONNEUTROPENIC PATIENTS
    COMETTA, A
    BAUMGARTNER, JD
    LEW, D
    ZIMMERLI, W
    PITTET, D
    CHOPART, P
    SCHAAD, U
    HERTER, C
    EGGIMANN, P
    HUBER, O
    RICOU, B
    SUTER, P
    AUCKENTHALER, R
    CHIOLERO, R
    BILLE, J
    SCHEIDEGGER, C
    FREI, R
    GLAUSER, MP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) : 1309 - 1313